NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
40.51
Dollar change
+0.16
Percentage change
0.40
%
IndexRUT P/E- EPS (ttm)-2.73 Insider Own13.75% Shs Outstand42.00M Perf Week-0.22%
Market Cap1.70B Forward P/E33.20 EPS next Y1.22 Insider Trans-1.71% Shs Float36.24M Perf Month-6.74%
Enterprise Value1.37B PEG- EPS next Q-0.37 Inst Own100.05% Short Float22.38% Perf Quarter-21.70%
Income-104.94M P/S7.28 EPS this Y63.52% Inst Trans9.99% Short Ratio12.21 Perf Half Y-25.04%
Sales233.67M P/B4.97 EPS next Y208.93% ROA-24.69% Short Interest8.11M Perf YTD-26.84%
Book/sh8.15 P/C4.17 EPS next 5Y- ROE-33.98% 52W High57.28 -29.28% Perf Year60.37%
Cash/sh9.71 P/FCF- EPS past 3/5Y-65.92% -66.60% ROIC-25.32% 52W Low20.08 101.72% Perf 3Y173.53%
Dividend Est.- EV/EBITDA- Sales past 3/5Y47.49% - Gross Margin92.99% Volatility3.53% 4.30% Perf 5Y-
Dividend TTM- EV/Sales5.85 EPS Y/Y TTM42.86% Oper. Margin-46.72% ATR (14)1.75 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.54 Sales Y/Y TTM449.03% Profit Margin-44.91% RSI (14)41.60 Recom1.29
Dividend Gr. 3/5Y- - Current Ratio5.57 EPS Q/Q36.93% SMA20-2.54% Beta0.80 Target Price72.43
Payout- Debt/Eq0.21 Sales Q/Q183.68% SMA50-8.66% Rel Volume0.67 Prev Close40.35
Employees323 LT Debt/Eq0.21 EarningsMay 01 AMC SMA200-11.18% Avg Volume664.14K Price40.51
IPOOct 16, 2020 Option/ShortYes / Yes EPS/Sales Surpr.12.32% 8.15% Trades Volume444,827 Change0.40%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Resumed Oppenheimer Outperform $75
May-27-25Resumed H.C. Wainwright Buy $72
Nov-20-23Initiated Goldman Neutral $19
Jul-18-23Initiated William Blair Outperform $44
May-18-23Initiated Guggenheim Buy
Aug-01-22Initiated Barclays Overweight $40
Dec-21-21Initiated H.C. Wainwright Buy $40
Nov-23-21Initiated Oppenheimer Outperform $55
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
May-29-25 05:00PM
May-14-25 09:45AM
May-08-25 05:00PM
May-05-25 06:04PM
May-02-25 03:17AM
09:37PM Loading…
May-01-25 09:37PM
05:35PM
04:05PM
Apr-30-25 10:17AM
09:55AM
Apr-25-25 10:00AM
Apr-24-25 05:00PM
11:00AM
Apr-23-25 01:41PM
Apr-22-25 11:19AM
08:31AM Loading…
08:31AM
Apr-21-25 04:05PM
Mar-28-25 03:59PM
Mar-20-25 09:05AM
Mar-12-25 09:49PM
04:12PM
Mar-06-25 05:00PM
Feb-26-25 02:13AM
02:05AM
Feb-25-25 08:40AM
07:00AM
01:31AM
Feb-20-25 05:00PM
Jan-30-25 05:00PM
Jan-20-25 03:31PM
09:35AM Loading…
Jan-14-25 09:35AM
Jan-13-25 08:30AM
Dec-26-24 10:30AM
Dec-04-24 09:55AM
Nov-18-24 09:55AM
Nov-14-24 02:15AM
Nov-13-24 05:30PM
04:05PM
08:30AM
Nov-07-24 10:00AM
Nov-06-24 04:30PM
Nov-05-24 08:30AM
Oct-30-24 06:39AM
Oct-17-24 08:30AM
Oct-09-24 05:56PM
Sep-25-24 05:00PM
Aug-28-24 05:00PM
Aug-08-24 09:56PM
06:05PM
04:05PM
Jul-29-24 04:30PM
May-29-24 05:00PM
May-09-24 05:00PM
12:48PM
11:06AM
03:49AM
May-08-24 08:58PM
05:40PM
04:05PM
May-06-24 09:55AM
May-01-24 05:00PM
Apr-23-24 08:30AM
Apr-09-24 07:35AM
Apr-08-24 09:55AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
Mar-06-24 09:55AM
Mar-05-24 04:30PM
08:30AM
Mar-01-24 12:07AM
Feb-29-24 04:37PM
Feb-28-24 12:00PM
09:58AM
Feb-27-24 11:13PM
06:34AM
06:00AM
Feb-22-24 08:00AM
Feb-20-24 05:00PM
Jan-31-24 05:00PM
Jan-30-24 04:06AM
Jan-21-24 07:01AM
Dec-21-23 03:32PM
Dec-11-23 08:00AM
Dec-01-23 11:04PM
Nov-12-23 12:15PM
Nov-09-23 04:05PM
Nov-01-23 06:35PM
Sep-06-23 08:00AM
Aug-30-23 04:30PM
Aug-28-23 10:22AM
Aug-24-23 09:00AM
Aug-10-23 04:05PM
Aug-03-23 02:14PM
Aug-01-23 10:30PM
Jul-31-23 04:29PM
Jul-25-23 07:00AM
Jul-20-23 02:04PM
Jul-19-23 08:34PM
10:13AM
Jun-12-23 08:30AM
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farrow Jeffrey SSee RemarksJun 17 '25Sale40.4213,608550,03536,704Jun 18 04:07 PM
Farrow Jeffrey SOfficerJun 17 '25Proposed Sale40.4213,608550,088Jun 17 04:14 PM
Lin Elizabeth YeuChief Medical OfficerJun 16 '25Sale41.081,00641,3267,694Jun 17 04:07 PM
Lin Elizabeth YeuOfficerJun 16 '25Proposed Sale41.071,00641,321Jun 16 03:07 PM
Mottiwala AzizChief Commercial OfficerJun 09 '25Sale43.7617,500765,80047,557Jun 11 04:50 PM
Mottiwala AzizOfficerJun 09 '25Proposed Sale44.7417,500782,950Jun 09 10:21 AM
Azamian Bobak R.President/CEO and Board ChairMar 24 '25Sale50.006,000300,000824,106Mar 26 04:47 PM
Azamian Bobak R.OfficerMar 24 '25Proposed Sale50.006,000300,000Mar 24 05:35 PM
Mottiwala AzizChief Commercial OfficerMar 18 '25Sale46.293,643168,63471,979Mar 20 09:49 PM
Mottiwala AzizChief Commercial OfficerMar 20 '25Sale50.113,365168,62065,057Mar 20 09:49 PM
Mottiwala AzizChief Commercial OfficerMar 19 '25Sale47.403,557168,60268,422Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 20 '25Sale50.112,435122,01879,682Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 18 '25Sale46.292,605120,58584,660Mar 20 09:49 PM
Neervannan SeshadriChief Operating OfficerMar 19 '25Sale47.402,543120,53882,117Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 18 '25Sale46.293,341154,65558,057Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 19 '25Sale47.403,261154,57154,796Mar 20 09:49 PM
Wahl BryanGeneral CounselMar 20 '25Sale50.113,084154,53951,712Mar 20 09:49 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 18 '25Sale46.292,315107,16150,751Mar 20 09:48 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 20 '25Sale50.112,137107,08546,355Mar 20 09:48 PM
Whitfield Dianne C.Chief Human Resources OfficerMar 19 '25Sale47.402,259107,07748,492Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 20 '25Sale50.118,534427,63953,635Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 19 '25Sale47.408,551405,31762,169Mar 20 09:48 PM
Azamian Bobak R.President/CEO and Board ChairMar 18 '25Sale46.297,131330,09470,720Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 19 '25Sale47.401,25459,44023,617Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 18 '25Sale46.291,28459,43624,871Mar 20 09:48 PM
Farrow Jeffrey SSee RemarksMar 20 '25Sale50.111,18659,43022,431Mar 20 09:48 PM
Whitfield Dianne C.OfficerMar 20 '25Proposed Sale50.112,137107,093Mar 20 04:35 PM
Farrow Jeffrey SOfficerMar 20 '25Proposed Sale50.111,18659,435Mar 20 04:30 PM
Mottiwala AzizOfficerMar 20 '25Proposed Sale50.113,365168,632Mar 20 04:29 PM
Wahl BryanOfficerMar 20 '25Proposed Sale50.113,084154,550Mar 20 04:21 PM
Neervannan SeshadriOfficerMar 20 '25Proposed Sale50.112,435122,026Mar 20 04:18 PM
Azamian Bobak R.OfficerMar 20 '25Proposed Sale50.118,534427,669Mar 20 04:11 PM
Neervannan SeshadriOfficerMar 19 '25Proposed Sale47.402,543120,536Mar 19 03:27 PM
Wahl BryanOfficerMar 19 '25Proposed Sale47.403,261154,569Mar 19 03:24 PM
Azamian Bobak R.OfficerMar 19 '25Proposed Sale47.408,551405,311Mar 19 03:23 PM
Whitfield Dianne C.OfficerMar 19 '25Proposed Sale47.402,259107,075Mar 19 03:22 PM
Farrow Jeffrey SOfficerMar 19 '25Proposed Sale47.401,25459,439Mar 19 03:12 PM
Mottiwala AzizOfficerMar 19 '25Proposed Sale47.403,557168,599Mar 19 03:12 PM
Neervannan SeshadriOfficerMar 18 '25Proposed Sale46.282,605120,571Mar 18 04:31 PM
Wahl BryanOfficerMar 18 '25Proposed Sale46.283,341154,637Mar 18 04:26 PM
Mottiwala AzizOfficerMar 18 '25Proposed Sale46.283,643168,614Mar 18 04:26 PM
Whitfield Dianne C.OfficerMar 18 '25Proposed Sale46.282,315107,149Mar 18 04:20 PM
Azamian Bobak R.OfficerMar 18 '25Proposed Sale46.287,131330,055Mar 18 04:15 PM
Farrow Jeffrey SOfficerMar 18 '25Proposed Sale46.281,28459,429Mar 18 04:12 PM
Goldberg Andrew D.DirectorMar 07 '25Option Exercise12.897,00090,23013,350Mar 11 04:01 PM
LINK WILLIAM J PHDDirectorAug 12 '24Sale26.0835,000912,9610Aug 14 04:34 PM
FLYING L PARTNERS XI LLCDirectorAug 12 '24Proposed Sale26.8535,000939,750Aug 12 04:25 PM
Last Close
Jun 30 04:00PM ET
0.4003
Dollar change
+0.0692
Percentage change
20.90
%
PASG Passage Bio Inc daily Stock Chart
Index- P/E- EPS (ttm)-1.03 Insider Own14.38% Shs Outstand62.15M Perf Week19.56%
Market Cap24.88M Forward P/E- EPS next Y-0.70 Insider Trans-13.05% Shs Float53.21M Perf Month-11.38%
Enterprise Value-13.36M PEG- EPS next Q-0.20 Inst Own43.10% Short Float3.35% Perf Quarter5.07%
Income-63.46M P/S- EPS this Y31.21% Inst Trans-5.31% Short Ratio6.36 Perf Half Y-38.55%
Sales0.00M P/B0.53 EPS next Y5.11% ROA-56.03% Short Interest1.78M Perf YTD-29.41%
Book/sh0.75 P/C0.39 EPS next 5Y44.74% ROE-83.73% 52W High1.33 -69.90% Perf Year-56.11%
Cash/sh1.02 P/FCF- EPS past 3/5Y32.43% -1.48% ROIC-93.08% 52W Low0.26 55.76% Perf 3Y-85.50%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility12.29% 11.30% Perf 5Y-98.89%
Dividend TTM- EV/Sales- EPS Y/Y TTM33.11% Oper. Margin- ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.74 Sales Y/Y TTM- Profit Margin- RSI (14)53.02 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.74 EPS Q/Q16.44% SMA20-1.79% Beta1.64 Target Price6.00
Payout- Debt/Eq0.54 Sales Q/Q- SMA509.44% Rel Volume2.16 Prev Close0.33
Employees60 LT Debt/Eq0.46 EarningsMay 13 BMO SMA200-24.87% Avg Volume280.09K Price0.40
IPOFeb 28, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-8.70% - Trades Volume606,115 Change20.90%
Date Action Analyst Rating Change Price Target Change
Nov-29-24Resumed Wedbush Outperform $3 → $4
Sep-03-24Initiated Rodman & Renshaw Buy $7
Mar-08-22Downgrade JP Morgan Overweight → Neutral
Jan-19-22Downgrade Goldman Buy → Neutral $29 → $6
Jul-01-21Initiated Raymond James Outperform $29
Jun-15-21Initiated BTIG Research Buy $25
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Jun-23-25 07:00AM
May-13-25 07:00AM
Mar-07-25 12:00PM
Mar-04-25 07:00AM
Feb-26-25 07:00AM
07:00AM Loading…
Jan-10-25 07:00AM
Nov-30-24 06:55AM
Nov-14-24 07:29AM
Nov-13-24 07:00AM
Nov-06-24 07:00AM
Oct-24-24 07:00AM
Sep-23-24 09:36PM
07:00AM
Sep-19-24 01:25AM
Sep-16-24 07:00AM
07:52AM Loading…
Sep-10-24 07:52AM
Aug-30-24 07:00AM
Aug-08-24 07:00AM
Aug-06-24 07:00AM
Aug-01-24 12:30PM
07:00AM
Jul-25-24 07:13AM
Jul-16-24 07:43AM
07:00AM
Jun-18-24 09:35AM
Jun-05-24 07:30AM
May-21-24 08:00AM
May-16-24 12:00PM
May-14-24 01:54PM
07:00AM
07:00AM Loading…
Apr-22-24 07:00AM
Mar-07-24 12:00PM
Mar-06-24 01:52PM
Mar-05-24 07:00AM
Mar-04-24 07:00AM
Feb-27-24 07:00AM
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Dec-25-23 10:14PM
Dec-20-23 07:00AM
Nov-17-23 04:30PM
Nov-13-23 07:00AM
Oct-30-23 07:00AM
Oct-20-23 04:30PM
Sep-25-23 07:00AM
Aug-11-23 10:04AM
Aug-07-23 07:15AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-24-23 12:37PM
Jul-06-23 11:17AM
Jun-05-23 07:00AM
May-11-23 07:00AM
May-04-23 07:00AM
Apr-21-23 04:01PM
Apr-17-23 07:00AM
Mar-29-23 09:02AM
Mar-27-23 07:00AM
Mar-08-23 07:14AM
Mar-07-23 12:42AM
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-20-23 05:59PM
Feb-15-23 07:00AM
Jan-20-23 04:01PM
Jan-07-23 07:39AM
Dec-14-22 12:13PM
07:00AM
Nov-21-22 05:24AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:30AM
Oct-14-22 04:01PM
Oct-11-22 12:25PM
Oct-10-22 07:00AM
Sep-26-22 07:00AM
Aug-19-22 04:01PM
Aug-11-22 07:00AM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-28-22 07:30AM
Jul-21-22 04:01PM
Jul-12-22 08:19AM
Jul-06-22 07:00AM
Jun-09-22 07:30AM
Jun-08-22 07:30AM
Jun-01-22 10:19AM
07:30AM
May-20-22 04:01PM
May-18-22 07:00AM
May-16-22 07:00AM
May-09-22 07:00AM
May-04-22 10:55AM
May-03-22 02:13PM
May-02-22 04:01PM
Apr-22-22 04:01PM
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ORBIMED ADVISORS LLC10% OwnerJun 24 '25Sale0.35231,60081,0606,418,400Jun 26 05:10 PM
ORBIMED ADVISORS LLC10% OwnerJun 26 '25Sale0.33213,25770,3756,066,343Jun 26 05:10 PM
ORBIMED ADVISORS LLC10% OwnerJun 25 '25Sale0.33138,80045,8046,279,600Jun 26 05:10 PM
OrbiMed Private Investments VIStockholderJun 24 '25Proposed Sale0.351,076,120378,364Jun 24 06:48 PM
ORBIMED ADVISORS LLC10% OwnerApr 23 '25Sale0.3489,32830,3726,718,195Apr 24 05:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 22 '25Sale0.3478,04926,5376,807,523Apr 24 05:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 24 '25Sale0.3268,19521,8226,650,000Apr 24 05:38 PM
ORBIMED ADVISORS LLC10% OwnerApr 17 '25Sale0.3377,09025,4406,885,572Apr 17 06:10 PM
ORBIMED ADVISORS LLC10% OwnerApr 16 '25Sale0.3361,63820,3416,962,662Apr 17 06:10 PM
ORBIMED ADVISORS LLC10% OwnerApr 15 '25Sale0.3810,3263,9247,024,300Apr 17 06:10 PM
OrbiMed Private Investments VIStockholderApr 15 '25Proposed Sale0.38787,179301,490Apr 15 05:40 PM
Borthwick KathleenCFOFeb 11 '25Sale0.533,1831,68641,283Feb 12 04:21 PM
ORBIMED ADVISORS LLC10% OwnerJan 10 '25Sale0.66126,20983,2987,131,636Jan 14 05:17 PM
ORBIMED ADVISORS LLC10% OwnerJan 14 '25Sale0.6079,02447,4147,034,626Jan 14 05:17 PM
ORBIMED ADVISORS LLC10% OwnerJan 13 '25Sale0.6417,98611,5117,113,650Jan 14 05:17 PM
ORBIMED ADVISORS LLC10% OwnerJan 08 '25Sale0.6875,00751,0057,257,845Jan 08 06:09 PM
ORBIMED ADVISORS LLC10% OwnerJan 07 '25Sale0.7152,53637,3017,332,852Jan 08 06:09 PM
ORBIMED ADVISORS LLC10% OwnerJan 06 '25Sale0.7719,48115,0007,385,388Jan 08 06:09 PM
OrbiMed Private Investments VIStockholderJan 06 '25Proposed Sale0.831,140,740945,673Jan 06 04:57 PM
Lynx1 Capital Management LP10% OwnerDec 27 '24Buy0.65373,645241,0389,256,953Dec 31 04:05 PM
ORBIMED ADVISORS LLC10% OwnerDec 20 '24Sale0.60230,321138,1937,404,869Dec 26 04:34 PM
ORBIMED ADVISORS LLC10% OwnerDec 09 '24Sale0.8454,18145,5127,643,285Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 10 '24Sale0.808,0156,4127,635,270Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 11 '24Sale0.8080647,635,190Dec 11 05:32 PM
ORBIMED ADVISORS LLC10% OwnerDec 04 '24Sale0.7976,20060,1987,718,369Dec 06 07:07 PM
ORBIMED ADVISORS LLC10% OwnerDec 06 '24Sale0.8220,90317,1407,697,466Dec 06 07:07 PM
OrbiMed Private Investments VIStockholderDec 04 '24Proposed Sale0.892,985,5182,657,111Dec 04 07:03 PM
Worldwide Healthcare Trust PLCStockholderDec 04 '24Proposed Sale0.892,028,3071,805,193Dec 04 06:57 PM
Lynx1 Capital Management LP10% OwnerNov 25 '24Buy0.56259,998146,6658,686,953Nov 27 06:11 PM
Lynx1 Capital Management LP10% OwnerNov 26 '24Buy0.71167,055118,1918,854,008Nov 27 06:11 PM
Lynx1 Capital Management LP10% OwnerNov 27 '24Buy0.6729,30019,6638,883,308Nov 27 06:11 PM
ORBIMED ADVISORS LLC10% OwnerSep 19 '24Sale0.7139,30027,9037,794,569Sep 23 04:51 PM
ORBIMED ADVISORS LLC10% OwnerSep 17 '24Sale0.73111,40081,3227,859,500Sep 18 06:38 PM
ORBIMED ADVISORS LLC10% OwnerSep 16 '24Sale0.7463,10046,6947,970,900Sep 18 06:38 PM
ORBIMED ADVISORS LLC10% OwnerSep 18 '24Sale0.7325,63118,7117,833,869Sep 18 06:38 PM
Worldwide Healthcare Trust PLCOwnerSep 16 '24Proposed Sale0.81241,328194,752Sep 16 08:38 PM
OrbiMed Private Investments VIOwnerSep 16 '24Proposed Sale0.81927,572748,551Sep 16 08:36 PM
Last Close
Jun 30 04:00PM ET
9.59
Dollar change
-0.15
Percentage change
-1.54
%
PHAT Phathom Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-5.24 Insider Own45.79% Shs Outstand69.64M Perf Week1.27%
Market Cap669.52M Forward P/E- EPS next Y-0.40 Insider Trans0.13% Shs Float37.85M Perf Month122.51%
Enterprise Value1.02B PEG- EPS next Q-0.91 Inst Own47.30% Short Float29.16% Perf Quarter45.30%
Income-345.79M P/S8.18 EPS this Y42.39% Inst Trans-17.12% Short Ratio3.96 Perf Half Y27.87%
Sales81.86M P/B- EPS next Y87.00% ROA-106.28% Short Interest11.04M Perf YTD18.10%
Book/sh-4.86 P/C3.15 EPS next 5Y- ROE- 52W High19.71 -51.34% Perf Year-6.16%
Cash/sh3.04 P/FCF- EPS past 3/5Y-10.82% 12.50% ROIC-165.71% 52W Low2.21 333.94% Perf 3Y17.67%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin86.23% Volatility6.29% 18.03% Perf 5Y-78.77%
Dividend TTM- EV/Sales12.48 EPS Y/Y TTM-18.80% Oper. Margin-349.84% ATR (14)0.94 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.54 Sales Y/Y TTM3055.71% Profit Margin-422.42% RSI (14)65.49 Recom1.22
Dividend Gr. 3/5Y- - Current Ratio3.58 EPS Q/Q7.67% SMA209.25% Beta0.41 Target Price19.88
Payout- Debt/Eq- Sales Q/Q1391.58% SMA5067.43% Rel Volume0.50 Prev Close9.74
Employees427 LT Debt/Eq- EarningsMay 01 BMO SMA2009.21% Avg Volume2.79M Price9.59
IPOOct 25, 2019 Option/ShortYes / Yes EPS/Sales Surpr.-18.82% -1.71% Trades Volume1,401,936 Change-1.54%
Date Action Analyst Rating Change Price Target Change
Feb-14-25Initiated Cantor Fitzgerald Overweight $23
May-03-24Initiated Stifel Buy $24
Jan-05-24Reiterated Needham Buy $23 → $26
Aug-09-23Initiated H.C. Wainwright Buy $28
May-11-23Upgrade Evercore ISI In-line → Outperform
Mar-13-23Initiated Craig Hallum Buy $21
Oct-21-22Initiated Jefferies Buy $16
May-06-22Downgrade Evercore ISI Outperform → In-line
May-12-21Upgrade Goldman Sell → Neutral $40 → $48
Feb-17-21Initiated BMO Capital Markets Outperform $63
Jun-23-25 04:15PM
07:59AM
Jun-16-25 08:00AM
Jun-09-25 09:55AM
Jun-06-25 12:45PM
12:27PM Loading…
12:27PM
May-15-25 07:59AM
May-08-25 09:35AM
May-02-25 03:02AM
May-01-25 04:15PM
12:09PM
08:15AM
07:00AM
Apr-28-25 07:59AM
Apr-23-25 08:00AM
08:00AM Loading…
Apr-16-25 08:00AM
Apr-08-25 07:09AM
Apr-03-25 11:25AM
08:00AM
Apr-01-25 04:15PM
08:00AM
Mar-31-25 07:59AM
Mar-07-25 02:08AM
Mar-06-25 09:10AM
08:00AM
Mar-05-25 07:21AM
Feb-24-25 08:00AM
Jan-29-25 08:00AM
Dec-12-24 09:39AM
Dec-11-24 08:00AM
09:35AM Loading…
Dec-06-24 09:35AM
Nov-19-24 12:00PM
Nov-08-24 06:02AM
Nov-07-24 09:20AM
08:00AM
Nov-06-24 07:21AM
Nov-04-24 08:00AM
Oct-28-24 08:00AM
Oct-27-24 12:00PM
Aug-29-24 08:00AM
Aug-19-24 08:00AM
Aug-08-24 09:20AM
08:00AM
Jul-30-24 08:00AM
Jul-29-24 07:59AM
Jul-18-24 08:00AM
Jun-09-24 07:00AM
Jun-07-24 06:17AM
May-28-24 08:00AM
May-15-24 08:00AM
May-13-24 11:02AM
May-10-24 08:00AM
May-09-24 09:15AM
08:00AM
May-03-24 08:02AM
Apr-29-24 08:00AM
Apr-22-24 03:30AM
Apr-19-24 03:03PM
11:02AM
Apr-05-24 06:30PM
Apr-03-24 08:00AM
Mar-26-24 08:00AM
Mar-08-24 03:05PM
01:57AM
Mar-07-24 01:51PM
01:38PM
08:00AM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Dec-14-23 08:00AM
Dec-06-23 08:00AM
Nov-28-23 08:00AM
Nov-09-23 09:34AM
08:00AM
Nov-01-23 05:00PM
Oct-30-23 08:00AM
Oct-25-23 08:01AM
Sep-26-23 08:01AM
Sep-05-23 08:00AM
Aug-21-23 08:00AM
Aug-10-23 08:01AM
Aug-09-23 10:26AM
Aug-07-23 02:34PM
Jul-14-23 04:40PM
Jul-10-23 08:26AM
Jul-07-23 08:38AM
06:52AM
Jun-12-23 08:01AM
Jun-09-23 04:01PM
Jun-01-23 09:55AM
08:00AM
May-27-23 09:07AM
May-26-23 09:55AM
May-25-23 09:55AM
May-23-23 07:41PM
04:01PM
04:00PM
May-10-23 08:00AM
May-09-23 08:00AM
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Topper James NDirectorMay 21 '25Buy3.863,78014,60959,403May 23 04:06 PM
Topper James NDirectorMay 14 '25Buy3.326,30020,91955,623May 15 04:17 PM
Topper James NDirectorMay 13 '25Buy3.161,1203,54349,323May 15 04:17 PM
Topper James NDirectorMay 09 '25Buy3.2235,602114,61635,602May 13 04:13 PM
Topper James NDirectorMay 12 '25Buy3.0412,60138,30148,203May 13 04:13 PM
Parikh AsitDirectorMay 06 '25Buy2.605,00013,00090,500May 08 05:27 PM
Parikh AsitDirectorMay 07 '25Buy2.405,00011,98495,500May 08 05:27 PM
Henderson MollyCFO and CBOApr 07 '25Sale4.553,67816,74089,868Apr 08 05:01 PM
Parikh AsitDirectorSep 10 '24Option Exercise11.727,50087,90093,000Mar 21 04:46 PM
Parikh AsitDirectorMar 13 '25Buy4.4210,00044,20085,500Mar 17 04:27 PM
Henderson MollyCFO and CBOJan 21 '25Sale6.596,58343,37193,546Jan 23 04:24 PM
Nabulsi AzmiChief Operating OfficerJan 21 '25Sale6.597,88651,957233,390Jan 23 04:21 PM
Curran TerriePresident and Chief ExecutiveJan 21 '25Sale6.5919,109125,884360,465Jan 23 04:19 PM
Nabulsi AzmiChief Operating OfficerDec 19 '24Sale8.001,1188,944239,303Dec 20 04:21 PM
Henderson MollyCFO and CBODec 19 '24Sale8.001,29110,32898,156Dec 20 04:20 PM
KARBE FRANKDirectorDec 13 '24Buy7.9312,50099,08457,000Dec 16 08:05 AM
Parikh AsitDirectorDec 13 '24Buy8.1210,00081,24875,500Dec 16 08:05 AM
Nabulsi AzmiChief Operating OfficerJul 15 '24Sale11.7210,901127,760240,421Jul 17 02:52 PM
Henderson MollyCFO and CBOJul 15 '24Sale11.724,32550,68999,447Jul 17 02:51 PM
Curran TerriePresident and Chief ExecutiveJul 15 '24Sale11.7233,848396,699377,734Jul 17 02:50 PM
Last Close
Jun 30 04:00PM ET
50.89
Dollar change
-0.20
Percentage change
-0.39
%
MIRM Mirum Pharmaceuticals Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-1.61 Insider Own19.18% Shs Outstand49.45M Perf Week1.22%
Market Cap2.52B Forward P/E- EPS next Y-0.49 Insider Trans-2.02% Shs Float40.03M Perf Month15.66%
Enterprise Value2.56B PEG- EPS next Q-0.33 Inst Own93.48% Short Float15.53% Perf Quarter10.65%
Income-77.34M P/S6.65 EPS this Y39.83% Inst Trans1.90% Short Ratio14.45 Perf Half Y20.68%
Sales379.25M P/B10.79 EPS next Y56.25% ROA-11.52% Short Interest6.22M Perf YTD23.07%
Book/sh4.72 P/C9.08 EPS next 5Y- ROE-33.06% 52W High54.23 -6.17% Perf Year54.87%
Cash/sh5.61 P/FCF- EPS past 3/5Y12.58% 4.14% ROIC-14.09% 52W Low33.11 53.70% Perf 3Y147.40%
Dividend Est.- EV/EBITDA- Sales past 3/5Y160.13% - Gross Margin76.99% Volatility2.62% 3.22% Perf 5Y142.68%
Dividend TTM- EV/Sales6.75 EPS Y/Y TTM57.12% Oper. Margin-20.12% ATR (14)1.52 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.04 Sales Y/Y TTM69.31% Profit Margin-20.39% RSI (14)66.61 Recom1.10
Dividend Gr. 3/5Y- - Current Ratio3.22 EPS Q/Q44.27% SMA204.24% Beta0.97 Target Price68.60
Payout- Debt/Eq1.36 Sales Q/Q61.20% SMA5012.16% Rel Volume0.91 Prev Close51.09
Employees322 LT Debt/Eq1.35 EarningsMay 07 AMC SMA20015.53% Avg Volume430.37K Price50.89
IPOJul 18, 2019 Option/ShortYes / Yes EPS/Sales Surpr.9.06% 13.38% Trades Volume393,695 Change-0.39%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $73
Apr-17-24Initiated Stifel Buy $48
Dec-18-23Reiterated H.C. Wainwright Buy $60 → $58
Nov-20-23Resumed JP Morgan Overweight $37
Nov-13-23Initiated Morgan Stanley Overweight $60
Oct-24-23Initiated Cantor Fitzgerald Overweight $50
Oct-17-23Resumed Evercore ISI Outperform $62
Sep-20-23Initiated JMP Securities Mkt Outperform $70
Sep-01-22Initiated Citigroup Buy $38
Sep-20-21Initiated JP Morgan Overweight $30
Jun-24-25 12:15PM
Jun-17-25 12:36PM
Jun-13-25 01:57PM
Jun-11-25 11:30AM
Jun-10-25 08:40PM
11:31AM Loading…
Jun-06-25 11:31AM
Jun-03-25 11:41AM
May-19-25 08:30AM
May-14-25 04:05PM
May-09-25 06:00PM
08:30AM
May-08-25 12:13PM
07:08AM
03:29AM
May-07-25 09:17PM
09:17PM Loading…
09:17PM
05:25PM
04:01PM
May-06-25 05:05PM
May-05-25 10:00AM
May-04-25 06:45PM
Apr-30-25 08:30AM
Apr-28-25 08:30AM
Apr-25-25 09:40AM
Apr-14-25 08:30AM
Apr-10-25 07:00PM
Apr-03-25 09:34AM
Mar-28-25 11:30AM
Mar-27-25 08:30AM
Mar-24-25 05:17PM
12:24PM Loading…
12:24PM
Mar-21-25 12:37PM
Mar-10-25 08:00PM
Feb-27-25 10:56AM
02:22AM
Feb-26-25 05:15PM
04:01PM
11:48AM
09:55AM
Feb-24-25 08:30AM
07:31AM
Feb-19-25 04:04PM
Feb-10-25 07:00PM
Jan-24-25 12:00PM
Jan-14-25 08:50AM
Jan-13-25 08:30AM
Jan-10-25 06:30PM
Jan-06-25 04:04PM
Dec-12-24 11:30AM
Dec-10-24 06:00PM
Dec-06-24 06:46AM
Nov-14-24 08:00AM
Nov-13-24 02:09AM
Nov-12-24 09:15AM
08:00AM
Nov-08-24 06:30PM
Nov-07-24 04:30PM
Nov-04-24 04:30PM
Oct-31-24 10:02AM
08:30AM
Oct-23-24 08:49AM
Oct-10-24 07:30PM
08:30AM
Oct-09-24 05:18PM
Sep-10-24 08:45PM
Sep-06-24 01:31PM
11:31AM
Aug-28-24 04:01PM
Aug-19-24 11:06AM
Aug-09-24 07:00PM
Aug-08-24 11:01AM
Aug-07-24 05:25PM
04:01PM
Jul-31-24 04:30PM
Jul-29-24 07:28AM
Jul-25-24 08:30AM
Jul-12-24 01:22PM
Jul-10-24 07:00PM
Jul-09-24 10:37AM
Jul-08-24 11:38AM
08:30AM
Jun-28-24 02:26PM
08:30AM
Jun-25-24 11:31AM
Jun-18-24 11:14AM
05:46AM
Jun-17-24 08:00AM
Jun-16-24 05:00PM
Jun-10-24 10:00PM
Jun-07-24 11:30AM
Jun-06-24 09:30AM
Jun-05-24 04:05PM
Jun-03-24 06:46AM
May-31-24 08:30AM
May-29-24 08:30AM
May-28-24 10:02AM
May-18-24 07:00AM
May-13-24 09:40AM
May-10-24 07:30PM
01:55PM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairey WilliamDirectorJun 11 '25Sale48.423,203155,0912,500Jun 13 04:18 PM
WILLIAM C FAIREYDirectorJun 11 '25Proposed Sale48.423,203155,091Jun 11 04:05 PM
Ramasastry SairaDirectorJun 03 '25Option Exercise14.122,50035,3002,500Jun 04 04:11 PM
Ramasastry SairaDirectorJun 02 '25Sale46.205,703263,4920Jun 04 04:11 PM
Ramasastry SairaDirectorJun 03 '25Sale45.742,500114,3520Jun 04 04:11 PM
SAIRA RAMASASTRYDirectorJun 03 '25Proposed Sale45.742,500114,352Jun 03 05:07 PM
SAIRA RAMASASTRYDirectorJun 02 '25Proposed Sale46.205,703263,492Jun 02 06:43 PM
Howe JolandaSVP, GLOBAL CONTROLLERMar 18 '25Sale44.452,415107,3432,426Mar 19 05:40 PM
Howe JolandaSVP, GLOBAL CONTROLLERMar 17 '25Option Exercise2.9452,900155,52659,547Mar 18 09:30 PM
Howe JolandaSVP, GLOBAL CONTROLLERMar 17 '25Sale44.3557,6062,554,7634,841Mar 18 09:30 PM
Radovich PeterPRESIDENT AND COOMar 17 '25Sale44.217,879348,36418,672Mar 18 09:30 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERMar 17 '25Sale44.2127,2791,206,122138,641Mar 18 09:30 PM
Heron Patrick JDirectorMar 14 '25Buy44.1152823,291168,651Mar 18 05:04 PM
Heron Patrick JDirectorMar 17 '25Buy43.9321923168,672Mar 18 05:04 PM
JOLANDA MARIE HOWEOfficerMar 18 '25Proposed Sale44.452,415107,343Mar 18 04:12 PM
JOLANDA MARIE HOWEOfficerMar 17 '25Proposed Sale44.3654,7062,426,540Mar 17 04:21 PM
Heron Patrick JDirectorMar 10 '25Buy42.971,33557,363167,160Mar 12 04:51 PM
Heron Patrick JDirectorMar 11 '25Buy43.7796342,155168,123Mar 12 04:51 PM
Heron Patrick JDirectorMar 06 '25Buy43.891,33558,597165,245Mar 10 05:12 PM
Heron Patrick JDirectorMar 07 '25Buy43.2158025,064165,825Mar 10 05:12 PM
Heron Patrick JDirectorMar 04 '25Buy45.571,33560,830163,643Mar 06 05:30 PM
Heron Patrick JDirectorMar 05 '25Buy44.5526711,894163,910Mar 06 05:30 PM
Radovich PeterPRESIDENT AND COOMar 04 '25Sale45.5814,850676,92812,111Mar 05 04:28 PM
Radovich PeterOfficerMar 04 '25Proposed Sale45.5214,850675,956Mar 04 04:43 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERMar 03 '25Option Exercise2.9440,000117,440155,920Mar 04 04:26 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERMar 03 '25Sale46.9140,0001,876,353115,920Mar 04 04:26 PM
CHRISTOPHER PEETZOfficerMar 03 '25Proposed Sale46.9140,0001,876,280Mar 03 04:49 PM
Radovich PeterPRESIDENT AND COOFeb 03 '25Sale48.222,627126,68126,961Feb 04 05:30 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERFeb 03 '25Sale48.229,102438,921115,920Feb 04 05:30 PM
Howe JolandaSVP, GLOBAL CONTROLLERFeb 03 '25Sale48.221,06451,3094,232Feb 04 05:30 PM
Radovich PeterPRESIDENT AND COOJan 24 '25Sale47.923,177152,25629,588Jan 27 04:50 PM
Howe JolandaSVP, GLOBAL CONTROLLERJan 24 '25Sale47.9290243,2283,524Jan 27 04:48 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERJan 24 '25Sale47.926,837327,658125,022Jan 27 04:48 PM
Quan JoanneCHIEF MEDICAL OFFICERJan 17 '25Sale45.866,969319,5985,649Jan 21 04:21 PM
Radovich PeterPRESIDENT AND COOJan 07 '25Sale42.821,99885,54527,015Jan 08 04:44 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERJan 07 '25Sale42.827,489320,644119,359Jan 08 04:42 PM
Howe JolandaSVP, GLOBAL CONTROLLERJan 07 '25Sale42.8275032,1112,926Jan 08 04:38 PM
Howe JolandaSVP, GLOBAL CONTROLLERNov 14 '24Option Exercise2.942,5007,3504,926Nov 15 05:34 PM
Howe JolandaSVP, GLOBAL CONTROLLERNov 14 '24Sale47.102,500117,7522,426Nov 15 05:34 PM
Heron Patrick JDirectorSep 18 '24Buy37.401154,301162,308Sep 20 04:39 PM
Heron Patrick JDirectorSep 06 '24Buy41.582309,563162,193Sep 10 05:04 PM
Peetz ChristopherCHIEF EXECUTIVE OFFICERJul 23 '24Option Exercise2.9434,01399,862126,783Jul 24 05:32 PM
Howe JolandaSVP, GLOBAL CONTROLLERJul 02 '24Sale34.0037512,7502,426Jul 03 06:19 PM